中国·金沙9570(官方)登录入口

Be the most trusted biotech company

2023-01-05

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in the US
2022-12-27

Henlius and Fosun Pharma Entered into an Exclusive License Agreement for HANSIZHUANG in the US
2022-12-15

First Patient Dosed in a Phase 1 Clinical Study of Henlius Novel Anti-GARP and Anti-PD-1 Dual mAb Therapy in Australia
2022-12-15

HANSIZHUANG Granted Orphan Drug Designation in the European Union for Small Cell Lung Cancer
2022-12-09

First Patient Dosed in the Phase 1 Clinical Trial of Henlius’ Novel Anti-TIGIT Fc Fusion Protein HLX53
2022-12-05

Consul General in San Francisco visited Henlius US Innovation Centre
2022-12-02

The Phase 3 Clinical Study Results of Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of ESCC Released at ESMO Asia Congress 2022
2022-12-02

The Updated Results of Phase 3 Clinical Study of Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of ES-SCLC Released at ESMO Asia Congress 2022
2022-12-02

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Novel Anti-GARP mAb HLX60